Sarcoidosis pathophysiology: Difference between revisions
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Sarcoidosis}} | {{Sarcoidosis}} | ||
{{CMG}} {{AE}} | {{CMG}} {{AE}}Roshan Dinparasti Saleh M.D. | ||
==Overview== | ==Overview== | ||
| Line 10: | Line 10: | ||
[[antigen-presenting cells]] ([[macrophages]] and/or [[dendritic cells]]), (3) a [[T cell]] response in an effort to eliminate the antigen, and (4) [[granuloma]] formation. | [[antigen-presenting cells]] ([[macrophages]] and/or [[dendritic cells]]), (3) a [[T cell]] response in an effort to eliminate the antigen, and (4) [[granuloma]] formation. | ||
[[macrophages]] differentiate into [[epithelioid cells]], which gain secretory capability, lose phagocytic capacity, and fuse to form [[multinucleated giant cells]] which are cellular basis of [[granuloma]]s. Th2 cells also contribute to [[granuloma]] formation. These cells secrete [[fibronectin]] and [[CCL18]], which finally lead to macrophage-mediated [[collagen]] formation and [[fibrosis]] in 25% of patients with [[sarcoidosis]] <ref>Iannuzzi MC, Rybicki BA, Teirstein AS: Sarcoidosis. N Engl J Med 357:2153–2165, 2007.</ref>. | [[macrophages]] differentiate into [[epithelioid cells]], which gain secretory capability, lose phagocytic capacity, and fuse to form [[multinucleated giant cells]] which are cellular basis of [[granuloma]]s. Th2 cells also contribute to [[granuloma]] formation. These cells secrete [[fibronectin]] and [[CCL18]], which finally lead to macrophage-mediated [[collagen]] formation and [[fibrosis]] in 25% of patients with [[sarcoidosis]] <ref>Iannuzzi MC, Rybicki BA, Teirstein AS: Sarcoidosis. N Engl J Med 357:2153–2165, 2007.</ref>. | ||
It is estimaed that two possible immunologic scenarios play role in [[sarcoidosis]]: an intense immune reaction in patients with active disease, finally resulting in [[antigen]] clearance, or chronic disease with less inflammation but the inability to eradicate the [[antigen]] and chronic stimulation of the immune response, resulting in organ damage such as [[lung fibrosis]]<ref>Zissel G: Cellular activation in the immune response of sarcoidosis. Semin Respir Crit Care Med 35:307–315, 2014.</ref> | It is estimaed that two possible immunologic scenarios play role in [[sarcoidosis]]: an intense immune reaction in patients with active disease, finally resulting in [[antigen]] clearance, or chronic disease with less inflammation but the inability to eradicate the [[antigen]] and chronic stimulation of the immune response, resulting in organ damage such as [[lung fibrosis]]<ref>Zissel G: Cellular activation in the immune response of sarcoidosis. Semin Respir Crit Care Med 35:307–315, 2014.</ref>. | ||
==Histopathological Findings== | ==Histopathological Findings== | ||
[[Granulomatous inlammation]] is necessary/but not sufficient to establish a diagnosis of [[sarcoidosis]] in most cases<ref>Statement on sarcoidosis: Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med | |||
160:736–755, 1999.</ref>. Histologic features that suggest [[sarcoidosis]]: | |||
* Compact (organized) collection of [[mononuclear]] [[phagocytes]] ([[macrophages]] and [[epithelioid cells]]) | |||
* No [[necrosis]] within the sarcoid [[granuloma]] | |||
* Inclusions may be present within the sarcoid [[granuloma]], including [[asteroid bodies]], [[Schaumann bodies]], [[birefringent crystals]], and [[Hamazaki-Wesenberg bodies]](neither specific nor diagnostic) | |||
* [[Granulomatous inlammation]] in at least two organs(although not routinely performed)<ref>Rosen Y: Pathology of sarcoidosis. Semin Respir Crit Care Med 28(1):36–52, 2007.</ref> | |||
The first histopathological finding in the lung is a [[CD4+ T cell]] [[alveolitis]], followed by the development of [[noncaseating granuloma]]<ref>Thomas PD, Hunninghake GW: Current concepts of the pathogenesis of sarcoidosis. The American review of respiratory disease 1987, 135(3):747-760.</ref> | The first histopathological finding in the lung is a [[CD4+ T cell]] [[alveolitis]], followed by the development of [[noncaseating granuloma]]<ref>Thomas PD, Hunninghake GW: Current concepts of the pathogenesis of sarcoidosis. The American review of respiratory disease 1987, 135(3):747-760.</ref> | ||
[http://www.peir.net Images courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology] | [http://www.peir.net Images courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology] | ||
Latest revision as of 21:48, 14 May 2018
|
Sarcoidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Sarcoidosis pathophysiology On the Web |
|
American Roentgen Ray Society Images of Sarcoidosis pathophysiology |
|
Risk calculators and risk factors for Sarcoidosis pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Roshan Dinparasti Saleh M.D.
Overview
Sarcoidosis is a multisystem disorder of unknown etiology characterized by noncaseating granulomas in involved tissues. The lungs are affected most commonly, and pulmonary disease accounts for the majority of the morbidity and mortality associated with this disease. Other tissues commonly involved include the skin, eyes, and lymph nodes.
Pathophysiology
Granuloma formation is a hallmark of sarcoidosis disease. The underlying immunologic events include (1) exposure to antigens, (2) activation of antigen-presenting cells (macrophages and/or dendritic cells), (3) a T cell response in an effort to eliminate the antigen, and (4) granuloma formation. macrophages differentiate into epithelioid cells, which gain secretory capability, lose phagocytic capacity, and fuse to form multinucleated giant cells which are cellular basis of granulomas. Th2 cells also contribute to granuloma formation. These cells secrete fibronectin and CCL18, which finally lead to macrophage-mediated collagen formation and fibrosis in 25% of patients with sarcoidosis [1]. It is estimaed that two possible immunologic scenarios play role in sarcoidosis: an intense immune reaction in patients with active disease, finally resulting in antigen clearance, or chronic disease with less inflammation but the inability to eradicate the antigen and chronic stimulation of the immune response, resulting in organ damage such as lung fibrosis[2].
Histopathological Findings
Granulomatous inlammation is necessary/but not sufficient to establish a diagnosis of sarcoidosis in most cases[3]. Histologic features that suggest sarcoidosis:
- Compact (organized) collection of mononuclear phagocytes (macrophages and epithelioid cells)
- No necrosis within the sarcoid granuloma
- Inclusions may be present within the sarcoid granuloma, including asteroid bodies, Schaumann bodies, birefringent crystals, and Hamazaki-Wesenberg bodies(neither specific nor diagnostic)
- Granulomatous inlammation in at least two organs(although not routinely performed)[4]
The first histopathological finding in the lung is a CD4+ T cell alveolitis, followed by the development of noncaseating granuloma[5] Images courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology
References
- ↑ Iannuzzi MC, Rybicki BA, Teirstein AS: Sarcoidosis. N Engl J Med 357:2153–2165, 2007.
- ↑ Zissel G: Cellular activation in the immune response of sarcoidosis. Semin Respir Crit Care Med 35:307–315, 2014.
- ↑ Statement on sarcoidosis: Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 160:736–755, 1999.
- ↑ Rosen Y: Pathology of sarcoidosis. Semin Respir Crit Care Med 28(1):36–52, 2007.
- ↑ Thomas PD, Hunninghake GW: Current concepts of the pathogenesis of sarcoidosis. The American review of respiratory disease 1987, 135(3):747-760.